Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise

Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $32.80 Average PT from Analysts

Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Monte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Monte Rosa Therapeutics Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients at ASCO Genitourinary Cancers Symposium (ASCO GU)

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of “Moderate Buy” by Brokerages

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug

Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable

Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation

Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Monte Rosa Therapeutics (GLUE) Upgraded to Strong Buy: Here's Why

Monte Rosa's Experimental Drug Slashes Inflammation Linked To Heart Disease

Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects

Monte Rosa Therapeutics to Present Interim MRT-8102 Phase 1 Study Results

Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and NextCure (NASDAQ:NXTC)

Monte Rosa Scores A Win In Prostate Cancer, And Rockets To A Four-Year High

Monte Rosa Therapeutics Announces Compelling Clinical Activity of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients with Androgen Receptor Mutations

Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results

Monte Rosa: Looking Mispriced After Big Pharma Validation

BETTY NAMED CREATIVE AGENCY OF RECORD FOR GORILLA GLUE

Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases

Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Brighton Jones LLC Acquires New Stake in Monte Rosa Therapeutics, Inc. $GLUE

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases

Monte Rosa: H1 2026 NEK7 Protein Degrader MRT-8102 Data Could Be Added POC

Monte Rosa Therapeutics And The Promise Of Molecular Glue Degraders

Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis

Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates

Monte Rosa Therapeutics Announces Second Quarter 2025 Financial Results and Business Updates

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet

Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference